ResearcherUniversity of Notre DameActive in the last 2 years
Niranjan Awasthi
Matched on ORCID iD 0000-0002-6477-1029; OpenAlex author ID A5047602817. Sources: OpenAlex.
Their work
- Papers
- 18 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2011: 3 papers · 2012: 3 papers · 2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 18
- Editor's Note: Enhancement of Nab-paclitaxel Antitumor Activity Through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-26-0733↗
- Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review). Last author DOI 10.3892/or.2023.8643↗
- Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.05.037↗
- Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer. Co-author DOI 10.1111/jcmm.14242↗
- Pancreatic ductal adenocarcinoma cell secreted extracellular vesicles containing ceramide-1-phosphate promote pancreatic cancer stem cell motility. Co-author DOI 10.1016/j.bcp.2018.09.017↗
- Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Co-author DOI 10.18632/oncotarget.23684↗
- Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. Co-author DOI 10.18632/oncotarget.9029↗
- Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2014.12.027↗
- Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-13-0361↗
- Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Co-author DOI 10.1093/carcin/bgt227↗
- PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. First author DOI 10.1158/1535-7163.mct-12-1123↗
- Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. Co-author DOI 10.1186/1756-9966-32-12↗
- The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. Co-author DOI 10.1002/jcb.23405↗
- BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-12-0447↗
- Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0038477↗
- Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy. Co-author DOI 10.1007/s00280-010-1514-7↗
- Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. Co-author DOI 10.1111/j.1477-2574.2011.00333.x↗
- Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. Co-author DOI 10.1186/1471-2407-11-15↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Roderich Egbert Schwarz · 17 shared papers, 2011–2026 · strength 1.31
- Paper Editor's Note: Enhancement of Nab-paclitaxel Antitumor Activity Through Addition of Multitargeting Antiangiogenic Agent… DOI 10.1158/1535-7163.mct-26-0733↗
- Paper Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical … DOI 10.1016/j.canlet.2019.05.037↗
- Paper Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models… DOI 10.1111/jcmm.14242↗
- Margaret A. Schwarz · 16 shared papers, 2011–2026 · strength 1.27
- Paper Editor's Note: Enhancement of Nab-paclitaxel Antitumor Activity Through Addition of Multitargeting Antiangiogenic Agent… DOI 10.1158/1535-7163.mct-26-0733↗
- Paper Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical … DOI 10.1016/j.canlet.2019.05.037↗
- Paper Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models… DOI 10.1111/jcmm.14242↗
- Joshua H. Zhang · 1 shared paper, 2023 · strength 0.24
- Rolf A. Brekken · 3 shared papers, 2011–2015 · strength 0.14
- Paper Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. DOI 10.1016/j.canlet.2014.12.027↗
- Paper PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic… DOI 10.1158/1535-7163.mct-12-1123↗
- Paper Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. DOI 10.1186/1471-2407-11-15↗
- Norbert Kuc · 1 shared paper, 2018 · strength 0.08
- Katherine T. Ostapoff · 1 shared paper, 2013 · strength 0.04
- Bercin Kutluk Cenik · 1 shared paper, 2013 · strength 0.04
- Chenyue Zhang · 1 shared paper, 2013 · strength 0.04
- Amanda Kirane · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.